Education
About Us
Working with TipRanks
Follow Us
Enanta Pharmaceuticals (ENTA)
:ENTA
ENTA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.71 - $17.80
Previous CloseN/A
Volume330.58K
Average Volume (3M)445.37K
Market Cap
$134.61M
Enterprise Value$126.11M
Total Cash (Recent Filing)$84.35M
Total Debt (Recent Filing)$57.46M
Price to Earnings (P/E)―
Beta1.50
Next Earnings
May 12, 2025EPS Estimate
-1.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.95
Shares Outstanding21,332,544
10 Day Avg. Volume263,986
30 Day Avg. Volume445,369
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.02
Price to Cash Flow (P/CF)-2.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.94
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.86
Enterprise Value/Ebitda-1.34
Forecast
1Y Price Target
$14.40Price Target Upside132.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
---
Enanta Pharmaceuticals News
PremiumCompany Announcements
Enanta Pharmaceuticals Stockholders Approve Key Proposals in 2025
PremiumCompany Announcements
Enanta Pharmaceuticals Advances in Virology and Immunology
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsZelicapavir successfully met the study's primary virology endpoint in the pooled efficacy population, with a peak viral load reduction of 0.7 log on Day 9 compared to placebo.
Financial PerformanceEnanta ended 1Q25 with cash and marketable securities of $216.7M, which should fund operations into fiscal 2028, providing runway to achieve multiple milestones across their virology and immunology efforts.
Strategic PartnershipsManagement announced plans to evaluate potential partnership opportunities for advancing its RSV programs.
Bears Say
Clinical Data LimitationsRESOLVE-P shows a trend of symptom reduction with zelicapavir, but the sample size was small and it has yet to be validated for use in a Phase 3 registrational study.
Regulatory ChallengesClarity is needed for symptom improvement with zelicapavir, as there are no regulatory-approved symptom assessment tools for pediatric RSV currently.
Stock PerformanceEnanta shares have settled near multi-year lows with a lack of late-stage catalysts and visibility to approvals/market.
---
Ownership Overview
6.75% Insiders
14.50% Mutual Funds
22.71% Other Institutional Investors
44.79% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ENTA FAQ
What was Enanta Pharmaceuticals’s price range in the past 12 months?
Enanta Pharmaceuticals lowest stock price was $4.71 and its highest was $17.80 in the past 12 months.
What is Enanta Pharmaceuticals’s market cap?
Enanta Pharmaceuticals’s market cap is $134.61M.
When is Enanta Pharmaceuticals’s upcoming earnings report date?
Enanta Pharmaceuticals’s upcoming earnings report date is May 12, 2025 which is in 48 days.
How were Enanta Pharmaceuticals’s earnings last quarter?
Enanta Pharmaceuticals released its earnings results on Feb 10, 2025. The company reported -$1.05 earnings per share for the quarter, beating the consensus estimate of -$1.353 by $0.303.
Is Enanta Pharmaceuticals overvalued?
According to Wall Street analysts Enanta Pharmaceuticals’s price is currently Undervalued.
Does Enanta Pharmaceuticals pay dividends?
Enanta Pharmaceuticals does not currently pay dividends.
What is Enanta Pharmaceuticals’s EPS estimate?
Enanta Pharmaceuticals’s EPS estimate is -1.15.
How many shares outstanding does Enanta Pharmaceuticals have?
Enanta Pharmaceuticals has 21,332,544 shares outstanding.
What happened to Enanta Pharmaceuticals’s price movement after its last earnings report?
Enanta Pharmaceuticals reported an EPS of -$1.05 in its last earnings report, beating expectations of -$1.353. Following the earnings report the stock price went up 14.082%.
Which hedge fund is a major shareholder of Enanta Pharmaceuticals?
Currently, no hedge funds are holding shares in ENTA
---
Enanta Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.40 (132.26% Upside)
$14.40 (132.26% Upside)
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $256.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.50%
12-Months-Change
Fundamentals
Return on Equity
-69.10%
Trailing 12-Months
Asset Growth
-18.64%
Trailing 12-Months
Company Description
Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
---
ENTA Stock 12 Month Forecast
Average Price Target
$14.40
▲(132.26% Upside)
Technical Analysis
Best Analysts Covering ENTA
1 Year
1 Year Success Rate
10/20 ratings generated profit
1 Year Average Return
+2.60%
reiterated a buy rating last month
Copying Liisa Bayko's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +2.60% per trade.
---